I’ve spent 11 years in the trenches of commercial ops and managed markets. I’ve sat through thousands of hours of conference presentations where the speakers talked about "synergy" while the audience checked their emails. I’m done with that. When you show up to an event like Access USA, you need to know exactly who you’re meeting, why they matter, and what you’re going to do about it on Monday morning.
Access USA is unique because it attempts to shove three distinct ecosystems under one roof. If you go in there thinking you’re just going to "do some networking," you are burning your travel budget. Let’s break down the mechanics of these events and how to actually extract value from them.
The Three Pillars: Mapping the Audience
Most attendees treat these conferences like a monolith. They aren’t. You are effectively attending three different types of summits simultaneously: the Payer/Managed Care summit, the Health System/Executive forum, and the Oncology/Site-of-Care operation. Here is how I map the "who" for my internal stakeholders.
Event Focus Key Stakeholder Type Decision-Making Priority Managed Care Strategy AMCP-aligned Payer Medical Directors/Formulary Leads Budget impact, utilization management, rebate structures. Health System Execs THMA-aligned C-suite/Pharmacy Directors Operational efficiency, hospital-level HTA, revenue capture. Oncology/Clinical Operations ACCC-aligned Oncology Admin/Oncologists Patient assistance, infusion center throughput, clinical pathways.Market Access vs. Prescriber Reach: A Crucial Distinction
The biggest mistake I see junior account managers make is treating Market Access like it’s just another form of "prescriber reach." It isn’t. When you are talking to an audience shaped by AMCP, you aren’t selling clinical efficacy—you’re selling predictability.
Prescriber reach is about https://pharmashots.com/33979/pharma-market-access-conferences-2026/ convincing a doctor your drug works. Market access is about convincing a health system that your drug doesn’t break their monthly budget. If you walk into a session at Access USA and start talking about the mechanism of action, you’ve already lost the room. Focus on the burden of administration. If your hub and specialty pharmacy models don’t alleviate the burden on the practice, no amount of clinical data will get you on the preferred formulary tier.. Exactly.
Payer Expectations and HTA Pressure
We are living in an era of intense Health Technology Assessment (HTA) pressure, even in the US. Payers are no longer just asking "Does it work?" They are asking "Is it worth this price point compared to the existing standard of care?"
At these summits, when you talk to payers, stop using the phrase "value-based care" unless you have the data to back it up. They want to hear about:
- Pricing and Affordability: How do your patient assistance and access programs bridge the gap for the underinsured without cannibalizing your commercial base? Real-World Evidence: Are you using digital tools in evidence generation to prove your drug reduces downstream hospitalizations? Formulary Execution: How does your product fit into existing clinical pathways, and what happens when it doesn't?
The Health System and the "Cookie Law" Problem
I know, the title of this section sounds random. But stay with me. Let me tell you about a situation I encountered thought they could save money but ended up paying more.. As a conference planner, I spend a lot of time looking at the digital ecosystems of our partners. When we look at how health systems and providers interface with patients, we see a massive disconnect in user experience.
Here's what kills me: ever notice those "cookie law info" plugin ui elements on health system portals? they are usually clunky, poorly designed, and represent exactly how patients feel when trying to navigate access. If your hub and specialty pharmacy models require the patient or the provider to jump through five different logins, that’s a failure of access. When you meet with health system executives at these events, ask them: "How many clicks does it take to start the prior authorization process?" If the answer is more than three, your product is going to be dropped for one that’s easier to prescribe.
Focusing on the Rare Disease Summit
If you are attending the rare disease summit track, the rules change entirely. You aren't playing the "formulary volume" game. You are playing the "patient journey" game. In rare disease, the payer isn't just looking at the P&L; they are looking at the media coverage risk. If your patient assistance program is slow, or if the hub is a black hole, you are creating a PR disaster for the health system.
When you are in these sessions, ask the speakers: "How are you reconciling the high cost of therapy with the provider's need for rapid patient initiation?" If you don't have a concrete answer to that, your product will stay in the pharmacy cabinet, not the infusion chair.
What Am I Doing on Monday?
This is the question I ask after every single conference. If you can’t answer this, you went to a party, not a business event. Here is my post-conference "Monday" audit:
The Spreadsheet Review: I look at my "who I actually met" list. Did I meet the actual formulary decision-maker, or just a vendor selling a SaaS platform? If I didn’t get a name that I can plug into a CRM for a follow-up, the meeting was a failure. The Tech Gap Analysis: I compare the digital tools I saw presented with the tools our own field teams use. If our hub platform is clunkier than what the competition is pitching, I’m calling our vendor on Tuesday. The HTA Reality Check: Did I hear a specific objection from a Payer or Health System exec that my team doesn't have an answer for? I pull the clinical and commercial leads into a room and draft a counter-narrative for our value dossier. The Patient Assistance Audit: I review our current patient assistance and access programs to see if we are actually meeting the needs discussed in the rare disease tracks. Are we too restrictive? Are we too generous in the wrong places?Final Thoughts: Stop Being Vague
Access USA is a tool. Like any tool, it can be used to build or it can be a total waste of capacity. If you walk away saying, "The networking was great," you’ve failed. Networking isn't a KPI. Getting a firm answer on how a specific IDN (Integrated Delivery Network) handles specialty pharmacy intake is a KPI. Getting a candid, off-the-record conversation about a major payer’s recent policy shift is a KPI.
Stop chasing the "synergy" buzzwords. Stop trying to find the "perfect" solution that streamlines everything. Look for the friction points—the broken UI, the delayed hub initiation, the misaligned HTA expectations—and solve them one by one. That’s how you actually get patients on therapy.
See you on the floor. I’ll be the one with the spreadsheet, looking for people who can actually explain the math behind their formulary decisions.